ArticleJournal of ovarian research2025
Protective effect of ammonium trichloride tellurate (AS101) on ovarian injury induced by chemotherapy drug doxorubicin in rats.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic synergistic interplay between ovarian antioxidant defense and angiogenesis sustains high egg production in laying hens.Journal of animal science and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo investigate the protective effect of ammonium trichloride tellurate (AS101) on doxorubicin induced ovarian function damage in rats.
methodsEighteen female SD rats were randomly divided into three groups with 6 rats in each group: group A blank control group (0.9% normal saline 0.1 ml intraperitoneally for 21 consecutive days), group B (0.9% normal saline 0.1 ml intraperitoneally for 5 days, doxorubicin 10 mg / kg intraperitoneally on day 6, and continued to be injected with normal saline for 15 days), group C (0.9% normal saline 0.1 ml intraperitoneally for 5 days, doxorubicin 10 mg / kg intraperitoneally on day 6, and continued to be injected with AS101 twice every other day). The contents to be recorded by the operator team include: (1) before operation: ① observe the general state of rats in each group and record the weight of rats. ② Vaginal smears of rats in each group were observed at the same time every day to observe the estrous cycle of rats. (2) After operation: ① observe the general state of rats in each group, read the weight of rats, and record the data Vaginal smears of rats in each group were observed at the same time every day after operation to observe the estrous cycle of rats. ③ At the end of the postoperative observation period, blood samples were taken from the tail of rats to measure the serum levels of estrogen 2 (E2), follicle stimulating hormone (FSH), and anti-M ü llerian hormone (AMH). ④ At the end of the observation period, the animals were sacrificed to observe the development of bilateral ovarian follicles. ⑤ At the end of the observation period, blood was taken from the abdominal aorta of rats after anesthesia, and the upper serum was separated after centrifugation at 3000 rpm. The levels of malondialdehyde (MDA), superoxide dismutase (SOD) and reactive oxygen species (ROS) were measured according to the operation methods of the kit instructions.
resultThe body weight of rats in group B was significantly lower than that in group A, while that in group C was significantly higher than that in group B (P < 0.05). The estrous cycle of rats in group B was disordered, and the estrous cycle of rats in group C was restored regularly (P < 0.05). The serum estradiol(E2) and AMH levels in group C were significantly higher than those in group B, and the FSH level was significantly lower than that in group B. Compared with group B, the number of primary follicles increased and the number of atretic follicles decreased in group C (P < 0.05). The SOD level in group B was lower than that in group A, and that in group C was higher than that in group B (P < 0.05). The levels of MDA and ROS in group B were higher than those in group A (P < 0.05), while those in group C were lower than those in group B (P < 0.05).
conclusionAS101 can protect the damage of doxorubicin on ovarian function in rats, and its mechanism is related to its antioxidant effect. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.